Cafepharma Today

Memorial Day Weekend 2025
We wish all our US visitors a safe and enjoyable holiday weekend. We remember those who have given their lives to defend and protect our country.

CP Today will resume on Tuesday, May 27

*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

What's Moving These 3 Biotechs?
Motley Fool
Friday, October 4, 2013 - 12:16pm
tags:
Ligand, Pfizer, Vivus, Omeros
2 Companies Suffering From Generic Competition and 1 That's Set to Benefit
Motley Fool
Friday, October 4, 2013 - 12:13pm
tags:
generics, GSK, Novartis, Ranbaxy
Should Drugmakers Pay Punitive Damages? Novartis Says No
Pharmalot
Friday, October 4, 2013 - 11:23am
tags:
Novartis
Amgen announces data from romosozumab, Prolia studies
The Fly on the Wall
Friday, October 4, 2013 - 11:17am
tags:
Amgen, romosozumab, Prolia, UCB, bone mineral density
Why AbbVie's Global Alliance With Galapagos Is Good News for Investors
Motley Fool
Friday, October 4, 2013 - 11:15am
tags:
AbbVie, Galapagos, cystic fibrosis
India's Glenmark puts contraceptive business up for sale, paper reports
Fierce Pharma
Friday, October 4, 2013 - 11:06am
tags:
Teva, M&A, India, Glenmark, contraceptives, Actavis
Germany's Merck sees long-term growth in cancer drug Erbitux
Yahoo/Reuters
Friday, October 4, 2013 - 10:27am
tags:
Erbitux, Merck KGaA, Avastin, colorectal cancer
Discovery Labs announces FDA approval of Surfaxin
Yahoo/Fly on the Wall
Friday, October 4, 2013 - 10:25am
tags:
Discovery Labs, FDA, Surfaxin, respiratory distress syndrome
Drug firm Ikaria on the block for more than $2 billion - sources
Yahoo/Reuters
Friday, October 4, 2013 - 10:23am
tags:
Ikaria, M&A
Biogen's new MS drug maintains efficacy long term -study
Yahoo/Reuters
Friday, October 4, 2013 - 10:18am
tags:
MS, multiple sclerosis, Biogen Idec, Tecfidera
Orexigen obesity drug Contrave filed in Europe
Pharma Times, UK
Friday, October 4, 2013 - 10:16am
tags:
Orexigen, Europe, Contrave, obesity
Medical device maker Echo Therapeutics announces wide-scale "cost-reduction" initiatives that will mean layoffs for 33% of the company's employees
Mass Device
Friday, October 4, 2013 - 10:15am
tags:
Echo Therapeutics, layoffs, devices
New class of psoriasis drugs being developed
Bloomberg
Friday, October 4, 2013 - 10:14am
tags:
psoriasis, Novartis, AstraZeneca, Amgen, Eli Lilly, Enbrel, secukinumab, brodalumab, IL-17 blockers
Boehringer unit that makes Johnson & Johnson Doxil to shut, WSJ says
Yahoo/Fly on the Wall
Friday, October 4, 2013 - 10:10am
tags:
JNJ, Doxil, drug shortages, ovarian cancer, Boehringer Ingelheim
J&J makes an R&D splash with $42M venture play, biotech collaborations
Fierce Biotech
Thursday, October 3, 2013 - 5:35pm
tags:
R&D, JNJ, Effimune, Merus, Novartis Venture Fund, Pfizer Venture Investments
FDA Issues First Warning For Failing To Pay Generic Facility Fees
Pharmalot
Thursday, October 3, 2013 - 5:32pm
tags:
generic facility fees, FDA, Allergan, Colgate Palmolive
Recent Developments With Northwest Bio Hint At Big Move In 3 To 4 Months
Seeking Alpha
Thursday, October 3, 2013 - 5:30pm
tags:
Northwest Biotherapeutics, DCVax, prostate cancer, brain cancer
Obesity drug makers jockey for position as analysts praise Vivus
Marketwatch
Thursday, October 3, 2013 - 5:29pm
tags:
obesity, Vivus, Belviq, Arena Pharmaceuticals, Contrave, Orexigen, Qsymia
Pfizer, Ligand Win U.S. Approval for Hot Flash Therapy
Bloomberg
Thursday, October 3, 2013 - 5:25pm
tags:
Pfizer, Ligand, hot flashes, menopause, osteoporosis, FDA, Duavee
Things Just Got A Little Brighter For Vivus
Seeking Alpha
Thursday, October 3, 2013 - 11:58am
tags:
Vivus, Qsymia

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.